PortalPublikationenLoss of the adhesion molecule CEACAM1 is associated with ear...

Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers

Standard

Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. / Luebke, Andreas M; Ricken, Wiebke; Kluth, Martina; Hube-Magg, Claudia; Schroeder, Cornelia; Büscheck, Franziska; Möller, Katharina; Dum, David; Höflmayer, Doris; Weidemann, Sören; Fraune, Christoph; Hinsch, Andrea; Wittmer, Corinna; Schlomm, Thorsten; Huland, Hartwig; Heinzer, Hans; Graefen, Markus; Haese, Alexander; Minner, Sarah; Simon, Ronald; Sauter, Guido; Wilczak, Waldemar; Meiners, Jan.

in: INT J CANCER, Jahrgang 147, Nr. 2, 15.07.2020, S. 575-583.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Luebke, AM, Ricken, W, Kluth, M, Hube-Magg, C, Schroeder, C, Büscheck, F, Möller, K, Dum, D, Höflmayer, D, Weidemann, S, Fraune, C, Hinsch, A, Wittmer, C, Schlomm, T, Huland, H, Heinzer, H, Graefen, M, Haese, A, Minner, S, Simon, R, Sauter, G, Wilczak, W & Meiners, J 2020, 'Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers', INT J CANCER, Jg. 147, Nr. 2, S. 575-583. https://doi.org/10.1002/ijc.32957

APA

Luebke, A. M., Ricken, W., Kluth, M., Hube-Magg, C., Schroeder, C., Büscheck, F., Möller, K., Dum, D., Höflmayer, D., Weidemann, S., Fraune, C., Hinsch, A., Wittmer, C., Schlomm, T., Huland, H., Heinzer, H., Graefen, M., Haese, A., Minner, S., ... Meiners, J. (2020). Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. INT J CANCER, 147(2), 575-583. https://doi.org/10.1002/ijc.32957

Vancouver

Luebke AM, Ricken W, Kluth M, Hube-Magg C, Schroeder C, Büscheck F et al. Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. INT J CANCER. 2020 Jul 15;147(2):575-583. https://doi.org/10.1002/ijc.32957

Bibtex

@article{0b5b0d2dcfd54b739a9f411046aeef77,
title = "Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers",
abstract = "Altered expression of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has been linked to adverse tumor features in various cancer types. To better understand the role of CEACAM1 in prostate cancer, we analyzed a tissue microarray containing tumor spots from 17,747 prostate cancer patients by means of immunohistochemistry. Normal prostate glands showed intense membranous CEACAM1 positivity. Immunostaining was interpretable in 13,625 cancers and was considered high in 28%, low in 43% and absent in 29% of tumors. Low and lost CEACAM1 expression was strongly linked to adverse tumor features including high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, positive surgical margin, a high number of genomic deletions and early biochemical recurrence (p < 0.0001 each). Subset analysis of molecularly defined cancer subsets revealed that these associations were strongest in V-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusion-positive cancers and that CEACAM1 loss was prognostic even in tumors harboring genomic deletions of the phosphatase and tensin homolog tumor suppressor (p < 0.0001). Multivariate analysis suggested that CEACAM1 analysis can provide independent prognostic information beyond established prognosis parameters at the stage of the initial biopsy when therapy decisions must be taken. In conclusion, loss of CEACAM1 expression predicts poor prognosis in prostate cancer and might provide clinically useful prognostic information particularly in cancers harboring the TMPRSS2:ERG fusion.",
author = "Luebke, {Andreas M} and Wiebke Ricken and Martina Kluth and Claudia Hube-Magg and Cornelia Schroeder and Franziska B{\"u}scheck and Katharina M{\"o}ller and David Dum and Doris H{\"o}flmayer and S{\"o}ren Weidemann and Christoph Fraune and Andrea Hinsch and Corinna Wittmer and Thorsten Schlomm and Hartwig Huland and Hans Heinzer and Markus Graefen and Alexander Haese and Sarah Minner and Ronald Simon and Guido Sauter and Waldemar Wilczak and Jan Meiners",
note = "{\textcopyright} 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.",
year = "2020",
month = jul,
day = "15",
doi = "10.1002/ijc.32957",
language = "English",
volume = "147",
pages = "575--583",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers

AU - Luebke, Andreas M

AU - Ricken, Wiebke

AU - Kluth, Martina

AU - Hube-Magg, Claudia

AU - Schroeder, Cornelia

AU - Büscheck, Franziska

AU - Möller, Katharina

AU - Dum, David

AU - Höflmayer, Doris

AU - Weidemann, Sören

AU - Fraune, Christoph

AU - Hinsch, Andrea

AU - Wittmer, Corinna

AU - Schlomm, Thorsten

AU - Huland, Hartwig

AU - Heinzer, Hans

AU - Graefen, Markus

AU - Haese, Alexander

AU - Minner, Sarah

AU - Simon, Ronald

AU - Sauter, Guido

AU - Wilczak, Waldemar

AU - Meiners, Jan

N1 - © 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

PY - 2020/7/15

Y1 - 2020/7/15

N2 - Altered expression of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has been linked to adverse tumor features in various cancer types. To better understand the role of CEACAM1 in prostate cancer, we analyzed a tissue microarray containing tumor spots from 17,747 prostate cancer patients by means of immunohistochemistry. Normal prostate glands showed intense membranous CEACAM1 positivity. Immunostaining was interpretable in 13,625 cancers and was considered high in 28%, low in 43% and absent in 29% of tumors. Low and lost CEACAM1 expression was strongly linked to adverse tumor features including high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, positive surgical margin, a high number of genomic deletions and early biochemical recurrence (p < 0.0001 each). Subset analysis of molecularly defined cancer subsets revealed that these associations were strongest in V-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusion-positive cancers and that CEACAM1 loss was prognostic even in tumors harboring genomic deletions of the phosphatase and tensin homolog tumor suppressor (p < 0.0001). Multivariate analysis suggested that CEACAM1 analysis can provide independent prognostic information beyond established prognosis parameters at the stage of the initial biopsy when therapy decisions must be taken. In conclusion, loss of CEACAM1 expression predicts poor prognosis in prostate cancer and might provide clinically useful prognostic information particularly in cancers harboring the TMPRSS2:ERG fusion.

AB - Altered expression of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has been linked to adverse tumor features in various cancer types. To better understand the role of CEACAM1 in prostate cancer, we analyzed a tissue microarray containing tumor spots from 17,747 prostate cancer patients by means of immunohistochemistry. Normal prostate glands showed intense membranous CEACAM1 positivity. Immunostaining was interpretable in 13,625 cancers and was considered high in 28%, low in 43% and absent in 29% of tumors. Low and lost CEACAM1 expression was strongly linked to adverse tumor features including high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, positive surgical margin, a high number of genomic deletions and early biochemical recurrence (p < 0.0001 each). Subset analysis of molecularly defined cancer subsets revealed that these associations were strongest in V-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusion-positive cancers and that CEACAM1 loss was prognostic even in tumors harboring genomic deletions of the phosphatase and tensin homolog tumor suppressor (p < 0.0001). Multivariate analysis suggested that CEACAM1 analysis can provide independent prognostic information beyond established prognosis parameters at the stage of the initial biopsy when therapy decisions must be taken. In conclusion, loss of CEACAM1 expression predicts poor prognosis in prostate cancer and might provide clinically useful prognostic information particularly in cancers harboring the TMPRSS2:ERG fusion.

U2 - 10.1002/ijc.32957

DO - 10.1002/ijc.32957

M3 - SCORING: Journal article

C2 - 32150281

VL - 147

SP - 575

EP - 583

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 2

ER -